Hipra is an European multinational pharmaceutical company focused on prevention and diagnosis for animal and human health, with a broad range of highly innovative vaccines and an advanced diagnostic service.
Hipra has a solid international presence and is located in more than 39 countries with our own subsidiaries, 2 production plants and 11 diagnostic centres. Moreover, our extensive international distribution network keeps open channels of marketing with nearly one hundred other countries, thereby covering the 5 continents.
Research is a priority. Hipra is the laboratory that has launched the most innovative vaccines and technology in the last ten years, with a total of 22 vaccines. The company allocates 10% of its annual revenue to R&D activities and 16% of its workforce is part of the R&D department.
Hipra lies in 6th place in the worldwide ranking of animal health vaccines.